Sangamo Therapeutics Inc (SGMO) - Total Assets
Based on the latest financial reports, Sangamo Therapeutics Inc (SGMO) holds total assets worth $88.64 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Sangamo Therapeutics Inc - Total Assets Trend (1996–2024)
This chart illustrates how Sangamo Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. Also see Sangamo Therapeutics Inc market capitalisation for the company's overall valuation and market capitalisation.
Sangamo Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Sangamo Therapeutics Inc's total assets of $88.64 Million consist of 50.9% current assets and 49.1% non-current assets. Review Sangamo Therapeutics Inc (SGMO) financial obligations to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 41.2% |
| Accounts Receivable | $4.60 Million | 4.5% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1996–2024)
This chart illustrates how Sangamo Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See latest Sangamo Therapeutics Inc stock price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Sangamo Therapeutics Inc's current assets represent 50.9% of total assets in 2024, an increase from 0.0% in 1996.
- Cash Position: Cash and equivalents constituted 41.2% of total assets in 2024, up from 0.0% in 1996.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 1996.
- Asset Diversification: The largest asset category is accounts receivable at 4.5% of total assets.
Sangamo Therapeutics Inc Competitors by Total Assets
Key competitors of Sangamo Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
Sangamo Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.88 | 1.35 | 4.60 |
| Quick Ratio | 0.88 | 1.35 | 4.95 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-6.05 Million | $14.97 Million | $516.12 Million |
Sangamo Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Sangamo Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 22.55 |
| Latest Market Cap to Assets Ratio | 0.27 |
| Asset Growth Rate (YoY) | -38.5% |
| Total Assets | $101.64 Million |
| Market Capitalization | $27.50 Million USD |
Valuation Analysis
Below Book Valuation: The market values Sangamo Therapeutics Inc's assets below their book value (0.27x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Sangamo Therapeutics Inc's assets decreased by 38.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Sangamo Therapeutics Inc (1996–2024)
The table below shows the annual total assets of Sangamo Therapeutics Inc from 1996 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $101.64 Million | -38.52% |
| 2023-12-31 | $165.32 Million | -70.61% |
| 2022-12-31 | $562.51 Million | -22.08% |
| 2021-12-31 | $721.92 Million | -23.08% |
| 2020-12-31 | $938.55 Million | +47.22% |
| 2019-12-31 | $637.52 Million | +7.98% |
| 2018-12-31 | $590.39 Million | +105.90% |
| 2017-12-31 | $286.74 Million | +81.61% |
| 2016-12-31 | $157.89 Million | -27.32% |
| 2015-12-31 | $217.24 Million | -10.68% |
| 2014-12-31 | $243.21 Million | +72.69% |
| 2013-12-31 | $140.84 Million | +70.64% |
| 2012-12-31 | $82.53 Million | -5.50% |
| 2011-12-31 | $87.34 Million | +38.63% |
| 2010-12-31 | $63.00 Million | -27.95% |
| 2009-12-31 | $87.44 Million | +28.87% |
| 2008-12-31 | $67.85 Million | -19.13% |
| 2007-12-31 | $83.90 Million | +50.41% |
| 2006-12-31 | $55.78 Million | +13.88% |
| 2005-12-31 | $48.98 Million | +41.06% |
| 2004-12-31 | $34.73 Million | -24.89% |
| 2003-12-31 | $46.23 Million | -17.78% |
| 2002-12-31 | $56.23 Million | -33.86% |
| 2001-12-31 | $85.02 Million | +23.35% |
| 2000-12-31 | $68.92 Million | +649.18% |
| 1999-12-31 | $9.20 Million | +128.17% |
| 1998-12-31 | $4.03 Million | -41.53% |
| 1997-12-31 | $6.90 Million | +1179.41% |
| 1996-12-31 | $539.00K | -- |
About Sangamo Therapeutics Inc
Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a ch… Read more